The Pharmaceutical Industry: Trends, Opportunities, & Challenges

 

Due to the COVID-19 situation, this event has been postponed and will be rescheduled at a later date. We apologize for the inconvenience.  

Join Fast Forward Medical Innovation to welcome Paul Hudson, CEO of Sanofi, as he talks about the current state of the pharmaceutical industry, including trends, opportunities, and challenges. Mr. Hudson’s experience at AstraZeneca, Novartis, and now at Sanofi affords him an ability to speak to industry trends, in addition to company-specific approaches. 

Moderated by Meilan Han, M.D., Professor of Internal Medicine-Pulmonary, the discussion will focus on the industry’s growth prospects with the rapid progress of biosimilars and disruptors in health technology, and the latest strategies and tactics, including business models, leadership styles, platform technologies, and innovations, in the constantly changing pharmaceutical, biotech, and healthcare reimbursement industries.

The discussion will also cover Sanofi’s philosophy on academic collaborations, and opportunities for U-M talent to either partner or integrate with the workforce at Sanofi. The event will end with an audience question & answer session.

Meet Our Guest

Paul Hudson, CEO, Sanofi

Paul Hudson joined Sanofi as CEO on September 1, 2019.

Previously CEO of Novartis Pharmaceuticals (2016-2019), where he was a member of the Executive Committee, Paul has an expansive international career in healthcare that spans the U.S., Japan, and Europe.

Prior to Novartis, he worked for AstraZeneca, where he held several increasingly senior positions and most recently carried out the roles of president, AstraZeneca United States and executive vice president, North America.

He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthélabo U.K.

CLICK HERE for a full bio.

February 19, 2021

FFMI PACE offers educational programs at all levels designed to support research and help participants navigate the road to successful biomedical commercialization, with the ultimate goal of positively impacting patient health.

X